These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 15001192

  • 21. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation.
    Arora-Gupta N, Davies P, McKiernan P, Kelly DA.
    Pediatr Transplant; 2004 Apr; 8(2):145-50. PubMed ID: 15049794
    [Abstract] [Full Text] [Related]

  • 22. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
    Prasad GV, Nash MM, McFarlane PA, Zaltzman JS.
    Nephron Clin Pract; 2004 Apr; 97(2):c35-40. PubMed ID: 15218328
    [Abstract] [Full Text] [Related]

  • 23. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 24. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study.
    Marcén R, Chahin J, Alarcón A, Bravo J.
    Transplant Proc; 2006 Oct 15; 38(8):2427-30. PubMed ID: 17097957
    [Abstract] [Full Text] [Related]

  • 25. Cardiovascular risk estimates and risk factors in renal transplant recipients.
    Krämer BK, Böger C, Krüger B, Marienhagen J, Pietrzyk M, Obed A, Paczek L, Mack M, Banas B.
    Transplant Proc; 2005 May 15; 37(4):1868-70. PubMed ID: 15919488
    [Abstract] [Full Text] [Related]

  • 26. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
    White M, Haddad H, Leblanc MH, Giannetti N, Pflugfelder P, Davies R, Isaac D, Burton J, Chan M, Azevedo E, Howlett J, Ignaszewski A, Busque S, Cantarovich M, Ferguson R, Genest J, Ross H.
    J Heart Lung Transplant; 2005 Jul 15; 24(7):798-809. PubMed ID: 15982605
    [Abstract] [Full Text] [Related]

  • 27. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year.
    Rowshani AT, Scholten EM, Bemelman F, Eikmans M, Idu M, Roos-van Groningen MC, Surachno JS, Mallat MJ, Paul LC, de Fijter JW, Bajema IM, ten Berge I, Florquin S.
    J Am Soc Nephrol; 2006 Jan 15; 17(1):305-12. PubMed ID: 16306168
    [Abstract] [Full Text] [Related]

  • 28. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients.
    Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V.
    J Hypertens; 2008 Nov 15; 26(11):2213-9. PubMed ID: 18854763
    [Abstract] [Full Text] [Related]

  • 29. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC, Srun SW, Wood EG, Belsha CW, Marshall DL, Ferdman BR.
    J Heart Lung Transplant; 2006 May 15; 25(5):518-22. PubMed ID: 16678029
    [Abstract] [Full Text] [Related]

  • 30. Effect of calcineurin inhibitors on low-density lipoprotein oxidation.
    Cofan F, Cofan M, Campos B, Guerra R, Campistol JM, Oppenheimer F.
    Transplant Proc; 2005 Nov 15; 37(9):3791-3. PubMed ID: 16386540
    [Abstract] [Full Text] [Related]

  • 31. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 15; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 32. The natural history of renal function following orthotopic heart transplant.
    Al Aly Z, Abbas S, Moore E, Diallo O, Hauptman PJ, Bastani B.
    Clin Transplant; 2005 Oct 15; 19(5):683-9. PubMed ID: 16146562
    [Abstract] [Full Text] [Related]

  • 33. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 34. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B.
    Transplant Rev (Orlando); 2009 Jan 27; 23(1):47-52. PubMed ID: 19027616
    [Abstract] [Full Text] [Related]

  • 35. Effects of different calcineurin inhibitors on sex hormone levels in transplanted male patients.
    Kantarci G, Sahin S, Uras AR, Ergin H.
    Transplant Proc; 2004 Jan 27; 36(1):178-9. PubMed ID: 15013339
    [Abstract] [Full Text] [Related]

  • 36. Arterial elasticity measurement in renal transplant recipients.
    Yildiz A, Fazlioglu M, Ersoy A, Gullulu M, Gullulu S, Yurtkuran M.
    Transplant Proc; 2007 Jun 27; 39(5):1455-7. PubMed ID: 17580160
    [Abstract] [Full Text] [Related]

  • 37. Impaired arterial compliance and aerobic endurance in kidney transplant recipients.
    Riess KJ, Gourishankar S, Oreopoulos A, Jones LW, McGavock JM, Lewanczuk RZ, Haykowsky MJ.
    Transplantation; 2006 Oct 15; 82(7):920-3. PubMed ID: 17038907
    [Abstract] [Full Text] [Related]

  • 38. Reduced incidence of hypertension after heterotopic cardiac transplantation compared with orthotopic cardiac transplantation: evidence that excision of the native heart contributes to post-transplant hypertension.
    Taegtmeyer AB, Crook AM, Barton PJ, Banner NR.
    J Am Coll Cardiol; 2004 Sep 15; 44(6):1254-60. PubMed ID: 15364328
    [Abstract] [Full Text] [Related]

  • 39. Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients.
    Kosch M, Hausberg M, Suwelack B.
    Transplantation; 2003 Nov 27; 76(10):1516-9. PubMed ID: 14657697
    [Abstract] [Full Text] [Related]

  • 40. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P, Shihab FS, Mulloy L, Henning AK, Gao J, Bartucci M, Holman J, First MR, OPTIMA Study Group.
    Transplantation; 2008 Jul 15; 86(1):88-95. PubMed ID: 18622283
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.